You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Positron Emission Tomography for Response Assessment in Desmoplastic Small Round Cell Tumor

Magnan, Heather MD*; Abramson, Sara J. MD; Price, Anita P. MD; Grewal, Ravinder K. MD; Merchant, Melinda S. MD, PhD*; LaQuaglia, Michael P. MD§; Meyers, Paul A. MD*

Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e3182707d4c
Online Articles: Original Articles
Abstract

Background: Desmoplastic small round cell tumors (DSRCT) typically have a large stromal component and often are extensively disseminated in the peritoneal cavity at diagnosis. These factors contribute to difficulty in quantifying response to chemotherapy using RECIST or WHO criteria. This study compares the overall disease response to chemotherapy by fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) in patients with DSRCT.

Methods: We conducted a retrospective chart review of 7 patients with DSRCT who were imaged by FDG-PET and CT at diagnosis and after 3 cycles of chemotherapy. Response to chemotherapy was graded according to EORTC metabolic response guidelines and RECIST.

Results: All tumors demonstrated some decrease in SUVmax (51%±21%) and longest diameter (23%±8%) with chemotherapy. The best response achieved by FDG-PET was a partial response in 6 patients and by CT was a partial response in 1 patient. Measured response was concordant between the 2 modalities in 2 patients.

Conclusions: In this small series response measurement by FDG-PET did not always correlate with response measurement by CT. A greater decrease in metabolic activity as compared with size was seen in all patients. Further studies are needed to define the role of FDG-PET in assessing early response of DSRCT to chemotherapy.

Author Information

Departments of *Pediatrics

Radiology

Radiology, Nuclear Medicine Service

§Surgery, Pediatric Surgery Service, Memorial Sloan-Kettering Cancer Center, New York, NY

Present address: Melinda S. Merchant, MD, PhD, The Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD.

Supported by Margaux’s Miracle Foundation.

The authors declare no conflict of interest.

Reprints: Heather Magnan, MD, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 (e-mail: magnanh@mskcc.org).

Received April 25, 2012

Accepted August 22, 2012

© 2013 by Lippincott Williams & Wilkins.